Showing results (61-70 of 192) with videos related to
Sort By:
Pageof 20
American Journal of Hematology|April 26, 2014
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromesRami S Komrokji, Eric Padron, Daohai Yu, et al.Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2007
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United StatesThomas F Goss, Agota Szende, Caroline Schaefer, et al.Blood|April 29, 2009
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Scott Smith, et al.Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary TaleHanadi Ramadan, Vu H Duong, Najla Al Ali, et al.Leukemia & Lymphoma|April 21, 2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failureVu H Duong, Najla Al Ali, Ling Zhang, et al.Blood|September 1, 2012
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndromeRami S Komrokji, Jeffrey E Lancet, Arlene S Swern, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndromeAlan F List, Maria R Baer, David P Steensma, et al.Clinical Lymphoma, Myeloma & Leukemia|September 24, 2013
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failureVu H Duong, Karen Lin, Tea Reljic, et al.Cancer|September 30, 2011
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndromeRami S Komrokji, Maria Corrales-Yepez, Najla Al Ali, et al.Blood|August 15, 2002
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phaseAlan F List, Kenneth J Kopecky, Cheryl L Willman, et al.Pageof 20